-
公开(公告)号:EP3698139A1
公开(公告)日:2020-08-26
申请号:EP18785368.4
申请日:2018-10-15
发明人: POYNARD, Thierry
IPC分类号: G01N33/574 , G16H50/30 , G16H10/00
-
-
公开(公告)号:EP3470843A1
公开(公告)日:2019-04-17
申请号:EP17306403.1
申请日:2017-10-16
发明人: POYNARD, Thierry
IPC分类号: G01N33/574 , G16H50/30
摘要: The present invention relates to new methods for assessing the risk of a patient, in particular with chronic liver disease, to develop primary liver cancer over time, using functions combining blood biochemical markers.
-
公开(公告)号:EP3513193A1
公开(公告)日:2019-07-24
申请号:EP17768442.0
申请日:2017-09-15
发明人: POYNARD, Thierry
IPC分类号: G01N33/576 , G01N33/92 , G06F19/00
-
公开(公告)号:EP2786287B1
公开(公告)日:2019-02-27
申请号:EP12794970.9
申请日:2012-11-30
发明人: POYNARD, Thierry
IPC分类号: G16H50/20
-
公开(公告)号:EP3296744A1
公开(公告)日:2018-03-21
申请号:EP16306186.4
申请日:2016-09-16
发明人: POYNARD, Thierry
IPC分类号: G01N33/576 , G01N33/92
CPC分类号: G01N33/576 , G01N33/92 , G06F19/00 , G06F19/34 , G16H50/30
摘要: The present invention relates to new methods for assessing NAFLD and NAH in a patient, combining measurement of serum markers through a logistic function.
摘要翻译: 本发明涉及用于评估患者中的NAFLD和NAH的新方法,其通过逻辑函数结合血清标记物的测量。
-
-
公开(公告)号:EP2786287A1
公开(公告)日:2014-10-08
申请号:EP12794970.9
申请日:2012-11-30
发明人: POYNARD, Thierry
IPC分类号: G06F19/00
CPC分类号: G06F19/18 , C12Q1/48 , G01N33/5091 , G06F19/00 , G16H50/20
摘要: The present invention relates to a new diagnosis method in the field of hepatology, combining measurement of serum markers and of liver elasticity.
-
9.
公开(公告)号:EP2600266A1
公开(公告)日:2013-06-05
申请号:EP11306611.2
申请日:2011-12-02
发明人: Poynard, Thierry
IPC分类号: G06F19/00
CPC分类号: G06F19/18 , C12Q1/48 , G01N33/5091 , G06F19/00 , G16H50/20
摘要: The present invention relates to a new diagnosis method in the field of hepatology, combining measurement of serum markers and of liver elasticity.
摘要翻译: 本发明涉及肝病学领域的新诊断方法,结合血清标志物测定和肝弹性。
-
公开(公告)号:EP3916389A1
公开(公告)日:2021-12-01
申请号:EP20305553.8
申请日:2020-05-27
发明人: POYNARD, Thierry
IPC分类号: G01N33/569
摘要: The invention relates to a new non-invasive test making it possible to detect infection by the SARS-CoV-2 virus in a patient, using values of Apolipoprotein A1 alone or in combination with other markers.
-
-
-
-
-
-
-
-
-